Evidence map›Paper›PMID 27989931›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.

Minoo Battiwalla, Shahrukh Hashmi, Navneet Majhail, Steven Pavletic, Bipin N Savani, Nonniekaye Shelburne

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Fatigue predicts impaired social adjustment in survivors of allogeneic hematopoietic cell transplantation (HCT).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Article
  18. Article
  19. Late effects of pediatric hematopoietic stem cell transplantation on left ventricular function, aortic stiffness and myocardial tissue characteristics.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Minoo BattiwallaHematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: battiwam@nhlbi.nih.gov.
Shahrukh HashmiMayo Clinic Transplant Center, Mayo Clinic, Rochester, Minnesota.
Navneet MajhailBlood and Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio.
Steven PavleticCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Bipin N SavaniHematology & Stem Cell Transplantation Section, Vanderbilt University Medical Center, Nashville, Tennessee.
Nonniekaye ShelburneDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, Maryland.

Funding

Intramural NIH HHS Z99 HL999999
6 · The paper itself

Abstract

Continual advances in hematopoietic cell transplantation (HCT) have greatly improved early transplantation-related mortality and broadened the applicability of this intense but curative therapy. With growing success there is increasing awareness of late complications, occurring ≥1 year after treatment, and their associated morbidity and mortality in HCT survivors. These late effects occur with a wide spectrum in terms of latency, intensity, reversibility, and lethality. There is a need to understand the biology, surveillance, management, and patient experience of HCT-related effects, as well as the health care and research infrastructure to manage this growing population. To address these needs, the National Cancer Institute and National Heart, Lung and Blood Institute cosponsored a 12-month initiative to identify barriers and knowledge gaps and to formulate research and practice recommendations. Six major areas of interest were identified: research methodology and study design, subsequent neoplasms, patient-centered outcomes, immune dysregulation and pathobiology, cardiovascular disease and associated risk factors, and health care delivery. These findings were presented during the 2016 workshop and revised based on public response. This report provides an overview of the National Institutes of Health HCT Late Effects Initiative process and recommendations.

Indexed as

Hematopoietic Stem Cell TransplantationDelivery of Health CareHealth Planning GuidelinesHumansLong Term Adverse EffectsNational Cancer Institute (U.S.)National Heart, Lung, and Blood Institute (U.S.)National Institutes of Health (U.S.)Research DesignTime FactorsUnited StatesHematopoietic cell transplantationLate effectsSurvivorship

Identifiers

PMID27989931
PMCPMC5182086

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.